Theseus Pharmaceuticals

Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. It focuses on the discovery, development and commercialization of transformative targeted therapies. The company was founded by William C. Shakespeare, David C. Dalgarno, Iain D. Dukes, Wei Sheng Huang and Victor M. Rivera on December 29, 2017 and is headquartered in Cambridge, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Theseus Pharmaceuticals is a technology-based company.

Theseus Pharmaceuticals, Inc. is a small company with large dreams backed by $100mn from Orbimed before it went public. The idea is to create pan-variant TKIs that can address all sorts of tumor resistance.

Theseus Pharmaceuticals: Orbimed-Backed Ex-ARIAD Team Developing Next-Gen TKI

-- Company to host virtual investor event to review updated data on May 25, 2023 at 5:30pm ET -- CAMBRIDGE, Mass. , April 26, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced that initial dose escalation data from the ongoing phase 1/2 study of THE-630 in advanced gastrointestinal stromal tumors (GIST) were accepted for online publication at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, in Chicago, Illinois.

Theseus Pharmaceuticals Initial Dose Escalation Results from Ongoing Phase 1/2 Trial of THE-630 Accepted for Online Publication at 2023 ASCO Annual Meeting

CAMBRIDGE, Mass. , April 11, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the company will participate virtually in the following upcoming investor conferences:

Theseus Pharmaceuticals to Participate in Upcoming Investor Conferences

The average of price targets set by Wall Street analysts indicates a potential upside of 128.8% in Theseus Pharmaceuticals, Inc. (THRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 128.83% Upside in Theseus Pharmaceuticals, Inc. (THRX): Can the Stock Really Move This High?

CAMBRIDGE, Mass. , March 28, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the company will participate in the Cantor Future of Oncology Virtual Symposium, taking place April 3-5, 2023.

Theseus Pharmaceuticals to Participate in the Cantor Future of Oncology Virtual Symposium

CRISPR Therapeutics

Kala Pharmaceuticals

Ligand Pharmaceuticals

New drug approvals and pipeline progress should maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position CRSP, LGND, THRX and KALA well amid volatility.

4 Biotech Stocks to Consider for Your Portfolio in 2023

Theseus Pharmaceuticals, Inc. (THRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Theseus Pharmaceuticals, Inc. (THRX) a New Buy Stock

THE-630 phase 1 preliminary dose-escalation data anticipated in Q2 2023; additional data including dose levels projected preclinically to provide pan-variant KIT coverage planned for Q4 2023 IND submission expected in Q4 2023 for THE-349 in EGFR-mutant NSCLC BCR-ABL prioritized as third development program for patients with CML and Ph+ ALL; development candidate nomination expected by early 2024 Current cash runway projected into Q3 2025 CAMBRIDGE, Mass. , March 9, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced business highlights and reported financial results for the fourth quarter and full year ended December 31, 2022.

Theseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results

AlTi Global, Inc.

BigBear.ai Holdings

Dragonfly Energy Holdings Corp

Enovix Corporation

Fate Therapeutics

Faraday Future Intelligent Electric

MotorSport Games

FiscalNote Holdings Inc

Vaxxinity, Inc.

Small-cap stocks are expected to perform well this year. The Bank of America Securities, in fact, is asking investors to consider small caps this year to hedge against a declining market.

The 5 Best and Worst Performing Small-Cap Stocks in January 2023

CAMBRIDGE, Mass. , Feb. 7, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the Company will participate virtually in the SVB Securities Global Biopharma Conference, taking place February 14-16, 2023.

Theseus Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference

Progressing Phase 1/2 clinical trial of THE-630 in advanced GIST; preliminary dose-escalation data anticipated in Q2 2023 with additional data expected in Q4 2023 IND submission for 4G EGFR inhibitor THE-349 expected in Q4 2023 Introducing BCR-ABL as target for third program, in development for CML and Ph+ ALL; development candidate nomination expected by early 2024 CAMBRIDGE, Mass. , Jan. 5, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced key anticipated milestones for 2023 and introduced its third development program, a pan-variant tyrosine kinase inhibitor (TKI) targeting BCR-ABL for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL as Target for Third Development Program

Potent single-molecule inhibition of all major classes of EGFR activating and resistance mutations, including C797X and T790M, with a high degree of kinome and wild-type EGFR selectivity Deep and durable tumor regressions in models of osimertinib-resistant EGFR-mutant NSCLC; substantial CNS activity and extended survival in intracranial mouse models IND submission to US FDA anticipated in H2 2023 CAMBRIDGE, Mass. , Oct. 26, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced preclinical data characterizing its fourth-generation epidermal growth factor receptor (EGFR) inhibitor, THE-349, will be detailed in a live poster presentation at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (ENA), taking place in Barcelona, Spain on October 26 – 28, 2022.

Theseus Pharmaceuticals Presents Preclinical Data Characterizing THE-349, its Fourth-Generation EGFR Inhibitor in Development for NSCLC, at the 34th EORTC-NCI-AACR Symposium

CAMBRIDGE, Mass. , Oct. 19, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced the appointment of Steven Stein, M.D.

Theseus Pharmaceuticals Appoints Steven Stein, M.D. to Board of Directors

THE-349 is a fourth-generation, potent and selective, small molecule designed to inhibit all major classes of EGFR activating and resistance mutations Preclinical data to be presented at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics IND submission anticipated in H2 2023 CAMBRIDGE, Mass. , Oct. 3, 2022 /PRNewswire/ --  Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced that it has nominated THE-349 as the development candidate for its epidermal growth factor receptor (EGFR) inhibitor program in non-small cell lung cancer (NSCLC).

Theseus Pharmaceuticals Nominates THE-349, a Fourth-Generation EGFR Inhibitor Development Candidate in Non-Small Cell Lung Cancer

CAMBRIDGE, Mass., Sept. 6, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the company will participate in-person at the following upcoming investor conferences: Conference: H.C.

Theseus Pharmaceuticals to Participate at Upcoming September Investor Conferences

THE-630 Phase 1/2 clinical trial enrolling patients; initial data expected in Q2 2023 Nomination of development candidate for fourth-generation epidermal growth factor receptor (EGFR) inhibitor program expected in Q3 2022; IND expected in 2023 $228.6 million in cash, cash equivalents, and investments as of June 30, 2022; expected to fund operations into the fourth quarter of 2024 CAMBRIDGE, Mass., Aug. 11, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced business and pipeline highlights and reported financial results for the second quarter ended June 30, 2022.

Theseus Pharmaceuticals Announces Business and Pipeline Highlights and Reports Second Quarter 2022 Financial Results

CAMBRIDGE, Mass. , Aug. 3, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that it will participate virtually in the 2022 Wedbush PacGrow Healthcare Conference, taking place August 9-10, 2022.

Theseus Pharmaceuticals to Participate Virtually in Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass. , May 18, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced the appointment of Don Hayden to its Board of Directors.

Theseus Pharmaceuticals Appoints Don Hayden to Board of Directors

THE-630 Phase 1/2 clinical trial actively enrolling patients with advanced gastrointestinal stromal tumors (GIST); initial data expected in 1H 2023 On track to nominate development candidate for fourth-generation epidermal growth factor receptor (EGFR) program targeting non-small cell lung cancer (NSCLC) in Q3 2022; IND expected in 2023 $237.0 million in cash, cash equivalents, and investments as of March 31, 2022, expected to fund operations into the second half of 2024 CAMBRIDGE, Mass. , May 12, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced business highlights and reported financial results for the first quarter ended March 31, 2022.

Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2022 Financial Results

Poster presentation details lead compounds demonstrating activity against EGFR variants that are resistant to all approved EGFR inhibitors Nomination of development candidate expected in Q3 2022; IND expected in 2023 CAMBRIDGE, Mass. , April 8, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced preclinical data characterizing next-generation pan-variant EGFR inhibitors that will be detailed in a live poster presentation at the American Association for Cancer Research (AACR) 2022 Annual Meeting, being held April 8-13, 2022 in New Orleans, Louisiana.

Theseus Pharmaceuticals Announces Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (EGFR) Inhibitors at the 2022 American Association for Cancer Research (AACR) Annual Meeting

CAMBRIDGE, Mass. , April 5, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that it will participate in the 21st Annual Needham Virtual Healthcare Conference, taking place April 11-14, 2022.

Theseus Pharmaceuticals to Participate Virtually in Needham Healthcare Conference

CAMBRIDGE, Mass., March 10, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced business highlights and reported financial results for the fourth quarter and full year ended December 31, 2021.

Theseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results

CAMBRIDGE, Mass., March 8, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the Company will present a poster highlighting the characterization of potent and selective next-generation EGFR inhibitors at the American Association for Cancer Research (AACR) 2022 Annual Meeting, being held April 8-13, 2022 in New Orleans, Louisiana.

Theseus Pharmaceuticals to Present Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (EGFR) Inhibitors at the 2022 American Association for Cancer Research (AACR) Annual Meeting

CAMBRIDGE, Mass., Feb. 9, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that Tim Clackson, Ph.D.

Theseus Pharmaceuticals to Participate Virtually in SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 2, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (Theseus) (NASDAQ: THRX), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the company's lead candidate THE-630, a small-molecule oral pan-variant KIT inhibitor, for the treatment of patients with advanced gastrointestinal stromal tumors (GIST).

News for Theseus Pharmaceuticals Stock (THRX)